These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 32014571)
1. A novel FFA1 agonist, CPU025, improves glucose-lipid metabolism and alleviates fatty liver in obese-diabetic (ob/ob) mice. Li Z; Liu C; Zhou Z; Hu L; Deng L; Ren Q; Qian H Pharmacol Res; 2020 Mar; 153():104679. PubMed ID: 32014571 [TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ. Li Z; Zhou Z; Deng F; Li Y; Zhang D; Zhang L Eur J Med Chem; 2018 Nov; 159():267-276. PubMed ID: 30296685 [TBL] [Abstract][Full Text] [Related]
3. ZLY032, the first-in-class dual FFA1/PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosis. Li Z; Zhou Z; Hu L; Deng L; Ren Q; Zhang L Pharmacol Res; 2020 Sep; 159():105035. PubMed ID: 32562818 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents. Li Z; Hu L; Wang X; Zhou Z; Deng L; Xu Y; Zhang L Bioorg Chem; 2019 Nov; 92():103254. PubMed ID: 31518760 [TBL] [Abstract][Full Text] [Related]
5. HWL-088, a new and highly effective FFA1/PPARδ dual agonist, attenuates nonalcoholic steatohepatitis by regulating lipid metabolism, inflammation and fibrosis. Hu L; Zhou Z; Deng L; Ren Q; Cai Z; Wang B; Li Z; Wang G J Pharm Pharmacol; 2020 Nov; 72(11):1564-1573. PubMed ID: 32734608 [TBL] [Abstract][Full Text] [Related]
6. Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents. Li Z; Chen Y; Zhou Z; Deng L; Xu Y; Hu L; Liu B; Zhang L Eur J Med Chem; 2019 Feb; 164():352-365. PubMed ID: 30605833 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold. Zhou Z; Cai Z; Zhang C; Yang B; Chen L; He Y; Zhang L; Li Z Bioorg Med Chem; 2022 Feb; 56():116615. PubMed ID: 35051813 [TBL] [Abstract][Full Text] [Related]
8. HWL-088, a new potent free fatty acid receptor 1 (FFAR1) agonist, improves glucolipid metabolism and acts additively with metformin in ob/ob diabetic mice. Chen Y; Ren Q; Zhou Z; Deng L; Hu L; Zhang L; Li Z Br J Pharmacol; 2020 May; 177(10):2286-2302. PubMed ID: 31971610 [TBL] [Abstract][Full Text] [Related]
9. Discovery of a structurally novel, potent, and once-weekly free fatty acid receptor 1 agonist for the treatment of diabetes. Wang B; Cai Z; Yao H; Jiao S; Chen S; Yang Z; Huang W; Ren Q; Cao Z; Chen Y; Zhang L; Li Z Eur J Med Chem; 2023 Jan; 245(Pt 1):114883. PubMed ID: 36343410 [TBL] [Abstract][Full Text] [Related]
10. Discovery of HWL-088: A highly potent FFA1/GPR40 agonist bearing a phenoxyacetic acid scaffold. Li Z; Ren Q; Wang X; Zhou Z; Hu L; Deng L; Guan L; Qiu Q Bioorg Chem; 2019 Nov; 92():103209. PubMed ID: 31487621 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and Structure-activity relationship studies of new thiazole-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes. Li Z; Qiu Q; Xu X; Wang X; Jiao L; Su X; Pan M; Huang W; Qian H Eur J Med Chem; 2016 May; 113():246-57. PubMed ID: 26945112 [TBL] [Abstract][Full Text] [Related]
12. TGR5 agonist ameliorates insulin resistance in the skeletal muscles and improves glucose homeostasis in diabetic mice. Huang S; Ma S; Ning M; Yang W; Ye Y; Zhang L; Shen J; Leng Y Metabolism; 2019 Oct; 99():45-56. PubMed ID: 31295453 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and evaluation of a series of novel phenylpropanoic acid derivatives agonists for the FFA1. Yang J; Gu E; Yan T; Shen D; Feng B; Tang C Chem Biol Drug Des; 2019 May; 93(5):900-909. PubMed ID: 30657643 [TBL] [Abstract][Full Text] [Related]
14. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats. Matsumoto K; Yoshitomi T; Ishimoto Y; Tanaka N; Takahashi K; Watanabe A; Chiba K J Pharmacol Exp Ther; 2018 Dec; 367(3):509-517. PubMed ID: 30217957 [TBL] [Abstract][Full Text] [Related]
15. Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents. Zhou Z; Ren Q; Jiao S; Cai Z; Geng X; Deng L; Wang B; Hu L; Zhang L; Yang Y; Li Z Eur J Med Chem; 2022 Feb; 229():114061. PubMed ID: 34954593 [TBL] [Abstract][Full Text] [Related]
16. Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models. Guo DY; Li DW; Ning MM; Dang XY; Zhang LN; Zeng LM; Hu YH; Leng Y Biochem Biophys Res Commun; 2015 Oct; 466(4):740-7. PubMed ID: 26417688 [TBL] [Abstract][Full Text] [Related]
17. In vitro and mouse in vivo characterization of the potent free fatty acid 1 receptor agonist TUG-469. Urban C; Hamacher A; Partke HJ; Roden M; Schinner S; Christiansen E; Due-Hansen ME; Ulven T; Gohlke H; Kassack MU Naunyn Schmiedebergs Arch Pharmacol; 2013 Dec; 386(12):1021-30. PubMed ID: 23861168 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of novel potent FFA1 agonists containing 2,3-dihydrobenzo[b][1,4]dioxine. Kong D; Guo S; Yang Y; Guo B; Xie X; Hu W Bioorg Med Chem Lett; 2019 Mar; 29(6):848-852. PubMed ID: 30685095 [TBL] [Abstract][Full Text] [Related]
19. Structure-based optimization of free fatty acid receptor 1 agonists bearing thiazole scaffold. Li Z; Xu X; Hou J; Wang S; Jiang H; Zhang L Bioorg Chem; 2018 Apr; 77():429-435. PubMed ID: 29433092 [TBL] [Abstract][Full Text] [Related]
20. A potent free fatty acid receptor 1 agonist with a glucose-dependent antihyperglycemic effect. Wang X; Xu Y; Feng S; Huang X; Meng X; Chen J; Guo L; Ge J; Zhang J; Chen J; Cheng L; Gu K; Zhang Y; Jiang Q; Ning X Chem Commun (Camb); 2019 Aug; 55(61):8975-8978. PubMed ID: 31290492 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]